Developer docs
API playgroundTry for free, no card

Search company profiles

Precision BioSciences

Full company profile

uuid0000ziy

Namestring
Precision BioSciences
Legal namestring
Precision BioSciences, Inc.
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Precision BioSciences is a clinical-stage biotechnology company founded in 2006 and headquartered in Durham, North Carolina, developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company targets diseases with high unmet medical need where current treatments are inadequate or non-curative, focusing on chronic hepatitis B (affecting over 300 million people globally) and Duchenne muscular dystrophy (approximately 15,000 patients in the US). Precision also maintains a portfolio of earlier-stage programs including PBGENE-PMM for primary mitochondrial myopathy, PBGENE-ALS for amyotrophic lateral sclerosis, and PBGENE-PCSK9 for cardiovascular disease.

The ARCUS platform is built on the I-CreI homing endonuclease originally discovered in Chlamydomonas reinhardtii algae. Its technical differentiation rests on three properties: a single-component architecture (only the I-CreI-derived nuclease both recognizes and cuts DNA), a small footprint of approximately 1,500 base pairs that enables delivery via AAV and accommodates larger payloads, and a 3-prime overhang cut that supports homology-directed repair. The wholly owned clinical programs — PBGENE-HBV (ELIMINATE-B Phase 1, 16 patients dosed across five cohorts, 1-log cccDNA reduction with durable pgRNA loss) and PBGENE-DMD (FUNCTION-DMD Phase 1/2 initiated at Arkansas Children's Hospital, designed to address roughly 60% of DMD patients via exons 45-55 excision) — represent the core value drivers.

The business model is partner-centric and milestone-driven. Precision generates revenue through upfront payments, development and regulatory milestone payments, and royalties on net sales of licensed programs, rather than through direct product sales. Major agreements include exclusive global licenses to TG Therapeutics for azer-cel in autoimmune indications (up to $288M in potential milestones plus tiered royalties) and to Imugene for azer-cel in oncology ($198M in potential milestones), plus historical collaborations with Eli Lilly, Novartis, and iECURE. Q1 2026 revenue of $10.8 million (versus less than $0.1 million in Q1 2025) was driven primarily by a TG Therapeutics milestone and a legacy ARCUS agriculture collaboration. As of Q1 2026, the company held $125.8 million in cash, with management stating this funds operations through 2028 to support the planned PBGENE-HBV and PBGENE-DMD clinical milestones.

Short descriptiontext

Precision BioSciences is a clinical-stage biotechnology company developing in vivo gene editing therapies using its proprietary ARCUS platform. Its lead programs — PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy — target diseases lacking curative treatments, with revenue generated through licensing and milestone payments from partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vivo gene editing, ARCUS genome editing, cell therapy products, gene editing pipeline, biopharmaceutical therapeutics
Industry3 codes
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Precision generates revenue through licensing agreements with partners like TG Therapeutics and Imugene. These agreements provide upfront payments, milestone payments upon achievement of clinical/regulatory/commercial events, and royalty payments on net sales. The TG Therapeutics deal includes up to $288M in potential milestone payments plus high-single-digit to low-double-digit royalties.

businesswire.com
2Collaboration Revenue
TypeSubscription Recurring
Description

Revenue from collaboration agreements including legacy ARCUS agriculture collaborations and research partnerships. Q1 2026 revenue of $10.8 million was driven by milestone revenue from TG Therapeutics license agreement and legacy ARCUS agriculture collaboration.

businesswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1ARCUS
Description

Proprietary genome editing platform based on naturally occurring I-CreI enzyme for gene insertion, removal, and repair in living cells and tissues

precisionbiosciences.com
+2 more records
Core offering1 text field

Precision BioSciences is a clinical-stage biopharmaceutical company developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company focuses on curative treatments for chronic hepatitis B, Duchenne muscular dystrophy, and other genetic diseases, with additional programs in oncology cell therapy through licensed assets including azer-cel.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 1-log (10-fold) reduction in cccDNA transcripts after two doses at 0.4 mg/kg in chronic hepatitis B patients
+5 more records
Product overview1 text field

Precision BioSciences is a clinical-stage gene editing company developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company's portfolio centers on PBGENE-HBV (gene editing therapy for chronic hepatitis B) and PBGENE-DMD (gene editing therapy for Duchenne muscular dystrophy), both wholly owned clinical-stage programs. Additional programs include PBGENE-PMM for primary mitochondrial myopathy, PBGENE-ALS for ALS, and PBGENE-PCSK9 for cardiovascular disease. The company has out-licensed azercabtagene zapreleucel (azer-cel) to Imugene for cancer and to TG Therapeutics for autoimmune diseases. The ARCUS platform, based on I-CreI homing endonuclease technology, enables sequence-specific DNA insertion, removal, and repair in living cells.

Product and service4 records
1PBGENE-HBV
CategoryGene Therapy
Description

Investigational in vivo gene editing therapy for chronic hepatitis B virus (HBV) infection, designed to use ARCUS nucleases to inactivate cccDNA and integrated HBV DNA for a functional cure.

2PBGENE-DMD
CategoryGene Therapy
Description

Investigational in vivo gene editing therapy for Duchenne muscular dystrophy (DMD), designed to use ARCUS to remove exons 45-55 of the dystrophin gene and restore dystrophin protein expression.

3Azercabtagene Zapreleucel (azer-cel)
CategoryCell Therapy
Description

Allogeneic CAR T-cell therapy candidate for CD19-positive B-cell malignancies, developed using ARCUS gene editing and out-licensed to Imugene and TG Therapeutics.

4PBGENE-PCSK9
CategoryGene Therapy
Description

Investigational in vivo gene editing therapy targeting the PCSK9 gene to lower LDL cholesterol levels for cardiovascular disease, licensed to iECURE.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierConcludedTypeStrategic or Co-development PartnerAnnounced on2024-04-16
Description

Previously collaborated on gene editing programs. Programs returned to Precision BioSciences and collaboration concluded in April 2024.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-09
Description

Exclusive global license agreement for azer-cel (azercabtagene zapreleucel) for non-cancer indications including autoimmune diseases. Precision received $17.5M upfront (mix of cash and equity) with potential for up to $288M in milestone payments and high-single-digit to low-double-digit royalties on net sales. TG Therapeutics advancing azer-cel in multiple sclerosis Phase 1 trial.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-08-15
Description

Exclusive global license to azer-cel for cancer indications. $29M upfront and potential near-term payments, $198M potential milestone payments, option to nominate up to three research programs each with $145M potential milestones and tiered royalties. Imugene assuming ongoing clinical execution for azer-cel in large B-cell lymphoma.

Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2022-06-14
Description

In vivo gene editing collaboration to develop potentially curative treatment for disorders including sickle cell disease. Novartis collaboration announced June 2022.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-09
Description

License and collaboration agreement for ARCUS gene insertion programs. iECURE advancing ECUR-506 for OTC deficiency using licensed ARCUS nuclease technology. Precision holds equity stake in iECURE plus milestone payments and royalties. ECUR-506 received FDA Fast Track designation, RMAT designation, and was selected for FDA CDRP Program.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-09-09
Description

Research, collaboration, and license agreement with University of Pennsylvania for preclinical development of gene editing products involving delivery of an ARCUS nuclease. Collaboration includes work on PCSK9-directed ARCUS nuclease.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-09-09
Description

Clinical collaboration to evaluate PBCAR269A in combination with nirogacestat in patients with relapsed or refractory multiple myeloma. SpringWorks providing nirogacestat while Precision provides PBCAR269A.

Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2021-01-07
Description

In vivo gene editing collaboration and license agreement for developing gene editing therapies. Precision granted rights to apply ARCUS technology in target indication areas. Transaction closed January 2021.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage in vivo gene editing company using CRISPR/Cas9 platform; advancing programs in HAE, ATTR, and other indications. Most direct competitor given both companies are pursuing in vivo gene editing with proprietary platforms and clinical-stage assets.

TypeDirect peer
Description

Developer of Cas9-based gene editing therapies including CASGEVY (approved sickle cell/beta-thalassemia). Competes with Precision in gene editing modality and shares target disease areas including hemoglobinopathies and rare genetic disorders.

TypeDirect peer
Description

Clinical-stage CRISPR-based gene editing company developing in vivo and ex vivo therapies. Directly competes with Precision's ARCUS platform in gene editing space, with overlapping focus on rare genetic diseases.

TypeDirect peer
Description

Clinical-stage base editing company developing precise gene editing therapies. Competes with Precision in next-generation gene editing technology and shares focus on in vivo editing applications.

TypeDirect peer
Description

Clinical-stage in vivo gene editing company focused on cardiovascular disease, including PCSK9 editing program. Direct competitor to Precision in in vivo gene editing for cardiovascular indications.

TypeDirect peer
Description

Clinical-stage gene editing company using zinc finger nuclease platform. Historical gene editing competitor with clinical assets in rare genetic diseases; comparable modality to ARCUS as engineered nuclease-based editing platform.

TypeDirect peer
Description

Commercial-stage DMD-focused company with approved therapies including ELEVIDYS gene therapy. Most direct competitor to Precision's PBGENE-DMD program in Duchenne muscular dystrophy space.

TypeEmerging player
Description

Clinical-stage gene therapy company focused on DMD with AAV-based approaches. Emerging competitor in DMD space targeting similar patient population as Precision's PBGENE-DMD.

TypeDirect peer
Description

Clinical-stage company developing functional cure therapies for chronic hepatitis B. Direct competitor to Precision's PBGENE-HBV program in chronic HBV treatment.

TypeEmerging player
Description

Clinical-stage genetic medicine company developing non-viral gene therapy using LNP delivery. Emerging player in in vivo gene editing/delivery space, with overlapping interest in liver-targeted therapies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors42 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Precision BioSciences

Precision BioSciences is a clinical-stage biotechnology company developing in vivo gene editing therapies using its proprietary ARCUS platform. Its lead programs — PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy — target diseases lacking curative treatments, with revenue generated through licensing and milestone payments from partners.

What Precision BioSciences does

Precision BioSciences is a clinical-stage biotechnology company founded in 2006 and headquartered in Durham, North Carolina, developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company targets diseases with high unmet medical need where current treatments are inadequate or non-curative, focusing on chronic hepatitis B (affecting over 300 million people globally) and Duchenne muscular dystrophy (approximately 15,000 patients in the US). Precision also maintains a portfolio of earlier-stage programs including PBGENE-PMM for primary mitochondrial myopathy, PBGENE-ALS for amyotrophic lateral sclerosis, and PBGENE-PCSK9 for cardiovascular disease.

The ARCUS platform is built on the I-CreI homing endonuclease originally discovered in Chlamydomonas reinhardtii algae. Its technical differentiation rests on three properties: a single-component architecture (only the I-CreI-derived nuclease both recognizes and cuts DNA), a small footprint of approximately 1,500 base pairs that enables delivery via AAV and accommodates larger payloads, and a 3-prime overhang cut that supports homology-directed repair. The wholly owned clinical programs — PBGENE-HBV (ELIMINATE-B Phase 1, 16 patients dosed across five cohorts, 1-log cccDNA reduction with durable pgRNA loss) and PBGENE-DMD (FUNCTION-DMD Phase 1/2 initiated at Arkansas Children's Hospital, designed to address roughly 60% of DMD patients via exons 45-55 excision) — represent the core value drivers.

The business model is partner-centric and milestone-driven. Precision generates revenue through upfront payments, development and regulatory milestone payments, and royalties on net sales of licensed programs, rather than through direct product sales. Major agreements include exclusive global licenses to TG Therapeutics for azer-cel in autoimmune indications (up to $288M in potential milestones plus tiered royalties) and to Imugene for azer-cel in oncology ($198M in potential milestones), plus historical collaborations with Eli Lilly, Novartis, and iECURE. Q1 2026 revenue of $10.8 million (versus less than $0.1 million in Q1 2025) was driven primarily by a TG Therapeutics milestone and a legacy ARCUS agriculture collaboration. As of Q1 2026, the company held $125.8 million in cash, with management stating this funds operations through 2028 to support the planned PBGENE-HBV and PBGENE-DMD clinical milestones.

Precision BioSciences firmographics

Firmographics
Name
Precision BioSciences
Legal name
Precision BioSciences, Inc.
Website
https://precisionbiosciences.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Short description
Precision BioSciences is a clinical-stage biotechnology company developing in vivo gene editing therapies using its proprietary ARCUS platform. Its lead programs — PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy — target diseases lacking curative treatments, with revenue generated through licensing and milestone payments from partners.
Ownership category
akta.pro rank

Precision BioSciences industry classification

Industry
Product category
Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • In vivo gene editing
  • ARCUS genome editing
  • Cell therapy products
  • Gene editing pipeline
  • Biopharmaceutical therapeutics

Where Precision BioSciences is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Precision BioSciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Milestone Payments: Precision generates revenue through licensing agreements with partners like TG Therapeutics and Imugene. These agreements provide upfront payments, milestone payments upon achievement of clinical/regulatory/commercial events, and royalty payments on net sales. The TG Therapeutics deal includes up to $288M in potential milestone payments plus high-single-digit to low-double-digit royalties.
  2. Collaboration Revenue: Revenue from collaboration agreements including legacy ARCUS agriculture collaborations and research partnerships. Q1 2026 revenue of $10.8 million was driven by milestone revenue from TG Therapeutics license agreement and legacy ARCUS agriculture collaboration.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Precision BioSciences product offering

Product offering

Core offering

Precision BioSciences is a clinical-stage biopharmaceutical company developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company focuses on curative treatments for chronic hepatitis B, Duchenne muscular dystrophy, and other genetic diseases, with additional programs in oncology cell therapy through licensed assets including azer-cel.

Product overview

Precision BioSciences is a clinical-stage gene editing company developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company's portfolio centers on PBGENE-HBV (gene editing therapy for chronic hepatitis B) and PBGENE-DMD (gene editing therapy for Duchenne muscular dystrophy), both wholly owned clinical-stage programs. Additional programs include PBGENE-PMM for primary mitochondrial myopathy, PBGENE-ALS for ALS, and PBGENE-PCSK9 for cardiovascular disease. The company has out-licensed azercabtagene zapreleucel (azer-cel) to Imugene for cancer and to TG Therapeutics for autoimmune diseases. The ARCUS platform, based on I-CreI homing endonuclease technology, enables sequence-specific DNA insertion, removal, and repair in living cells.

Differentiator

Problem solved

Functional benefit

Brands

  • ARCUS: Proprietary genome editing platform based on naturally occurring I-CreI enzyme for gene insertion, removal, and repair in living cells and tissues
  • PBGENE-HBV
  • PBGENE-DMD

Products and services

  • PBGENE-HBV Investigational in vivo gene editing therapy for chronic hepatitis B virus (HBV) infection, designed to use ARCUS nucleases to inactivate cccDNA and integrated HBV DNA for a functional cure.
  • PBGENE-DMD Investigational in vivo gene editing therapy for Duchenne muscular dystrophy (DMD), designed to use ARCUS to remove exons 45-55 of the dystrophin gene and restore dystrophin protein expression.
  • Azercabtagene Zapreleucel (azer-cel) Allogeneic CAR T-cell therapy candidate for CD19-positive B-cell malignancies, developed using ARCUS gene editing and out-licensed to Imugene and TG Therapeutics.
  • PBGENE-PCSK9 Investigational in vivo gene editing therapy targeting the PCSK9 gene to lower LDL cholesterol levels for cardiovascular disease, licensed to iECURE.

Quantifiable outcome

  • 1-log (10-fold) reduction in cccDNA transcripts after two doses at 0.4 mg/kg in chronic hepatitis B patients
  • +5 more outcomes

Companies that use Precision BioSciences

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Precision BioSciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Precision BioSciences partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered concluded, core, significant and minor.

  • Prevail TherapeuticsconcludedStrategic or Co-development Partner · 16 April 2024Previously collaborated on gene editing programs. Programs returned to Precision BioSciences and collaboration concluded in April 2024.
  • TG TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 9 January 2024Exclusive global license agreement for azer-cel (azercabtagene zapreleucel) for non-cancer indications including autoimmune diseases. Precision received $17.5M upfront (mix of cash and equity) with potential for up to $288M in milestone payments and high-single-digit to low-double-digit royalties on net sales. TG Therapeutics advancing azer-cel in multiple sclerosis Phase 1 trial.
  • ImugenecoreOEM/ Whitelabel/ Licensing Partner · 15 August 2023Exclusive global license to azer-cel for cancer indications. $29M upfront and potential near-term payments, $198M potential milestone payments, option to nominate up to three research programs each with $145M potential milestones and tiered royalties. Imugene assuming ongoing clinical execution for azer-cel in large B-cell lymphoma.
  • NovartissignificantStrategic or Co-development Partner · 14 June 2022In vivo gene editing collaboration to develop potentially curative treatment for disorders including sickle cell disease. Novartis collaboration announced June 2022.
  • iECUREcoreStrategic or Co-development Partner · 9 September 2021License and collaboration agreement for ARCUS gene insertion programs. iECURE advancing ECUR-506 for OTC deficiency using licensed ARCUS nuclease technology. Precision holds equity stake in iECURE plus milestone payments and royalties. ECUR-506 received FDA Fast Track designation, RMAT designation, and was selected for FDA CDRP Program.
  • University of PennsylvaniaminorStrategic or Co-development Partner · 9 September 2021Research, collaboration, and license agreement with University of Pennsylvania for preclinical development of gene editing products involving delivery of an ARCUS nuclease. Collaboration includes work on PCSK9-directed ARCUS nuclease.
  • SpringWorks TherapeuticsminorStrategic or Co-development Partner · 9 September 2021Clinical collaboration to evaluate PBCAR269A in combination with nirogacestat in patients with relapsed or refractory multiple myeloma. SpringWorks providing nirogacestat while Precision provides PBCAR269A.
  • Eli Lilly and CompanysignificantStrategic or Co-development Partner · 7 January 2021In vivo gene editing collaboration and license agreement for developing gene editing therapies. Precision granted rights to apply ARCUS technology in target indication areas. Transaction closed January 2021.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Precision BioSciences competitors and assessment

Company assessment

Direct peers

  • Intellia Therapeutics: Clinical-stage in vivo gene editing company using CRISPR/Cas9 platform; advancing programs in HAE, ATTR, and other indications. Most direct competitor given both companies are pursuing in vivo gene editing with proprietary platforms and clinical-stage assets.
  • CRISPR Therapeutics: Developer of Cas9-based gene editing therapies including CASGEVY (approved sickle cell/beta-thalassemia). Competes with Precision in gene editing modality and shares target disease areas including hemoglobinopathies and rare genetic disorders.
  • Editas Medicine: Clinical-stage CRISPR-based gene editing company developing in vivo and ex vivo therapies. Directly competes with Precision's ARCUS platform in gene editing space, with overlapping focus on rare genetic diseases.
  • Beam Therapeutics: Clinical-stage base editing company developing precise gene editing therapies. Competes with Precision in next-generation gene editing technology and shares focus on in vivo editing applications.
  • Verve Therapeutics: Clinical-stage in vivo gene editing company focused on cardiovascular disease, including PCSK9 editing program. Direct competitor to Precision in in vivo gene editing for cardiovascular indications.
  • Sangamo Therapeutics: Clinical-stage gene editing company using zinc finger nuclease platform. Historical gene editing competitor with clinical assets in rare genetic diseases; comparable modality to ARCUS as engineered nuclease-based editing platform.
  • Sarepta Therapeutics: Commercial-stage DMD-focused company with approved therapies including ELEVIDYS gene therapy. Most direct competitor to Precision's PBGENE-DMD program in Duchenne muscular dystrophy space.
  • Vir Biotechnology: Clinical-stage company developing functional cure therapies for chronic hepatitis B. Direct competitor to Precision's PBGENE-HBV program in chronic HBV treatment.

Emerging players

  • Solid Biosciences: Clinical-stage gene therapy company focused on DMD with AAV-based approaches. Emerging competitor in DMD space targeting similar patient population as Precision's PBGENE-DMD.
  • Generation Bio: Clinical-stage genetic medicine company developing non-viral gene therapy using LNP delivery. Emerging player in in vivo gene editing/delivery space, with overlapping interest in liver-targeted therapies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Precision BioSciences social profiles

Digital presence

Precision BioSciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Precision BioSciences leadership team

Management profile

Number of profiles

Profiles18 records

Precision BioSciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Precision BioSciences funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors42 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Precision BioSciences M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precision BioSciences

What does Precision BioSciences do?

Precision BioSciences is a clinical-stage biopharmaceutical company developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. The company focuses on curative treatments for chronic hepatitis B, Duchenne muscular dystrophy, and other genetic diseases, with additional programs in oncology cell therapy through licensed assets including azer-cel.

Is Precision BioSciences a public or private company?

Precision BioSciences is a public company. It is classified as public and is currently operating.

When was Precision BioSciences founded?

Precision BioSciences was founded in 2006. It employs 101 to 250 people.

Where is Precision BioSciences based?

Precision BioSciences is headquartered in Durham, United States, in the North America region.

How does Precision BioSciences make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are collaboration Revenue.

Who are Precision BioSciences's main competitors?

Direct peers on record are Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, Beam Therapeutics, Verve Therapeutics, Sangamo Therapeutics, Sarepta Therapeutics and Vir Biotechnology. Emerging players are Solid Biosciences and Generation Bio.

Does Precision BioSciences have an API?

No public API is recorded for Precision BioSciences.

What industry is Precision BioSciences in?

Precision BioSciences's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech TimesHepatitis B Cure Closer After Gene Editing Eliminates Viral Reservoir in Every Target-Dose PatientPrecision BioSciences presented Phase 1 data for PBGENE-HBV at AASLD 2026, showing 92% of patients with detectable pgRNA achieved undetectable levels. Biopsies confirmed cccDNA reductions up to 35-fold, and the company selected 0.4 mg/kg for a global Phase 2 study starting Q1 2027.American Banking and Market NewsPrecision BioSciences (NASDAQ:DTIL) Upgraded to Hold at Wall Street ZenWall Street Zen upgraded Precision BioSciences from Sell to Hold, while HC Wainwright reiterated Buy and Weiss Ratings restated Sell. The stock opened at $10.60, and the company reported Q4 EPS of -$0.28, beating the -$0.85 consensus. Analysts expect -$3.33 EPS for the current fiscal year.American Banking and Market NewsPrecision BioSciences, Inc. (DTIL) – What Are Brokerages Thinking About This Stock?Precision BioSciences shares opened at $9.87, with a consensus rating of Moderate Buy from five firms. The company reported a loss of $0.28 per share, beating estimates, and revenue of $1.25 million. Analysts predict a loss of $3.33 per share for the current year.MarketScreenerPrecision BioSciences, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2026Precision BioSciences reported a Q3 net loss of $7.59 million, down from $21.77 million a year earlier, with a basic loss per share of $0.28 versus $1.84. The company's pipeline includes in vivo gene editing candidates for hepatitis B and other diseases.Defense WorldPrecision BioSciences (DTIL) Set to Release Earnings on MondayPrecision BioSciences is set to release Q3 2026 earnings on Monday, November 2nd, with analysts expecting a loss of $0.85 per share and revenue of $1.38 million. The company's stock opened at $6.64, and analysts have a consensus rating of Moderate Buy with a target price of $32.25.MarketBeatPrecision BioSciences (DTIL) Set to Release Earnings on MondayPrecision BioSciences is set to release Q3 2026 earnings on Monday, November 2nd, with analysts expecting a loss of $0.85 per share and revenue of $1.38 million. The company's stock opened at $6.64, and analysts have a consensus rating of Moderate Buy with a target price of $32.25.Markets DailyPrecision BioSciences, Inc. (NASDAQ:DTIL) Stock Has Consensus Price Target of $32.25Precision BioSciences stock opened at $5.77, down 6.5%, after reporting a Q2 loss of $1.26 per share, missing the $0.80 consensus estimate. Analysts give a Moderate Buy consensus with a $32.25 price target, though Weiss Ratings and Wall Street Zen have downgraded to sell.Defense WorldPrecision BioSciences, Inc. (NASDAQ:DTIL) Stock Now Rated “Moderate Buy” by Sell-Side BrokeragesPrecision BioSciences received an average "Moderate Buy" rating from five analysts, with a $32.25 price target. The company reported Q2 EPS of -$1.26, missing the -$0.80 consensus, and analysts expect -$3.33 EPS for the fiscal year. The stock opened at $6.72.Markets DailyHead to Head Review: Oncocyte (NASDAQ:IMDX) and Precision BioSciences (NASDAQ:DTIL)Precision BioSciences outperforms Oncocyte on 9 of 14 factors, including higher revenue and earnings. Analysts rate Precision BioSciences more favorably with a higher consensus target price and greater upside. Oncocyte trades at a lower price-to-earnings ratio, making it the more affordable stock.Investing.comPrecision BioSciences at H.C. Wainwright conference: two shots on goal By Investing.comPrecision BioSciences outlined its two clinical programs at the H.C. Wainwright conference, targeting chronic hepatitis B and Duchenne muscular dystrophy. The company reported $112 million in cash and a runway through 2028, with data updates expected before year-end 2026.